The invention relates to substituted cyclodextrin (CD) compounds having C9 to C25 optionally substituted alkyl-based linker groups, which irreversibly inhibit viruses and are useful in the treatment of viral infections. While the compounds of the invention show virus inhibition in the nanomolar range they show no in-vitro toxicity in the same range of concentration.